ATE389638T1 - Aminobenzamidderivate als inhibitoren der glycogensynthasekinase-3- - Google Patents
Aminobenzamidderivate als inhibitoren der glycogensynthasekinase-3-Info
- Publication number
- ATE389638T1 ATE389638T1 AT02802307T AT02802307T ATE389638T1 AT E389638 T1 ATE389638 T1 AT E389638T1 AT 02802307 T AT02802307 T AT 02802307T AT 02802307 T AT02802307 T AT 02802307T AT E389638 T1 ATE389638 T1 AT E389638T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibitors
- glycogen synthase
- synthase kinase
- aminobenzamide derivatives
- aminobenzamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01204192 | 2001-11-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE389638T1 true ATE389638T1 (de) | 2008-04-15 |
Family
ID=8181175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02802307T ATE389638T1 (de) | 2001-11-01 | 2002-10-29 | Aminobenzamidderivate als inhibitoren der glycogensynthasekinase-3- |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20060063789A1 (de) |
| EP (1) | EP1442024B1 (de) |
| JP (1) | JP2005507420A (de) |
| KR (1) | KR20040062557A (de) |
| CN (1) | CN100436427C (de) |
| AT (1) | ATE389638T1 (de) |
| AU (1) | AU2002363177B2 (de) |
| BR (1) | BR0213790A (de) |
| CA (1) | CA2463823A1 (de) |
| DE (1) | DE60225709T2 (de) |
| DK (1) | DK1442024T3 (de) |
| EA (1) | EA007063B1 (de) |
| ES (1) | ES2303565T3 (de) |
| HU (1) | HUP0402245A3 (de) |
| IL (1) | IL161663A0 (de) |
| MX (1) | MXPA04004176A (de) |
| NO (1) | NO326889B1 (de) |
| NZ (1) | NZ531854A (de) |
| PL (1) | PL368920A1 (de) |
| PT (1) | PT1442024E (de) |
| WO (1) | WO2003037877A1 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1483283A4 (de) | 2002-03-13 | 2007-04-11 | Signum Biosciences Inc | Modulation der proteinmethylierung und phosphoproteinphosphat |
| EA200500721A1 (ru) * | 2002-11-28 | 2005-12-29 | Шеринг Акциенгезельшафт | Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств |
| DE10322911A1 (de) * | 2003-05-21 | 2004-12-16 | Bayer Materialscience Ag | Verfestigungsstabile blockierte Polyisocyanate |
| BR122019017579B8 (pt) * | 2003-08-15 | 2021-07-27 | Novartis Ag | 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica |
| EP1734963A4 (de) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen |
| WO2006084033A1 (en) * | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| EP1885454A2 (de) | 2005-05-04 | 2008-02-13 | DeveloGen Aktiengesellschaft | Verwendung von gsk-3-hemmern zur prävention und behandlung von pankreatischen autoimmunkrankheiten |
| EP2258359A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| EP2314289A1 (de) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba-rezeptor-vermittelte modulation von neurogenese |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| EP2222647B1 (de) | 2006-10-23 | 2015-08-05 | Cephalon, Inc. | Kondensierte bicyclische derivate von 2,4-diaminopyrimidin als alk- und c-met-inhibitoren |
| CL2008000197A1 (es) | 2007-01-26 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EP2152079A4 (de) | 2007-06-04 | 2011-03-09 | Avila Therapeutics Inc | Heterocyclische verbindungen und ihre verwendung |
| EP2214486A4 (de) * | 2007-10-19 | 2011-03-09 | Avila Therapeutics Inc | Heteroarylverbindungen und ihre verwendungen |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| WO2009071535A1 (en) * | 2007-12-03 | 2009-06-11 | Boehringer Ingelheim International Gmbh | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| AU2009239430B2 (en) | 2008-04-21 | 2015-01-22 | Signum Biosciences, Inc. | Compounds, compositions and methods for making the same |
| EP2321341B1 (de) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CA2789711C (en) * | 2010-02-17 | 2014-08-05 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
| CN103003264B (zh) | 2010-05-21 | 2014-08-06 | 切米利亚股份公司 | 嘧啶衍生物 |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| ES2675510T3 (es) | 2011-02-18 | 2018-07-11 | Endo Pharmaceuticals Inc. | Compuestos aminoindano y uso de los mismos en el tratamiento del dolor |
| CA2830129C (en) | 2011-03-24 | 2016-07-19 | Chemilia Ab | Novel pyrimidine derivatives |
| US9044482B2 (en) | 2012-08-15 | 2015-06-02 | Asana Biosciences, Llc | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |
| HK1211589A1 (zh) | 2012-08-23 | 2016-05-27 | Alios Biopharma, Inc. | 用於治疗副粘病毒病毒性感染的化合物 |
| CN105764916B (zh) | 2013-06-05 | 2021-05-18 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
| SG11201605539SA (en) | 2014-01-10 | 2016-08-30 | Glaxosmithkline Ip No 2 Ltd | Hydroxy formamide derivatives and their use |
| WO2017156527A1 (en) * | 2016-03-11 | 2017-09-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease |
| CN106632021A (zh) * | 2016-09-27 | 2017-05-10 | 中国药科大学 | 2‑取代异烟酸类化合物、其制备方法及其用途 |
| US20220133740A1 (en) | 2019-02-08 | 2022-05-05 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| CN112876420B (zh) * | 2019-11-29 | 2023-01-24 | 沈阳化工研究院有限公司 | 一种硫代苯甲酰衍生物及其应用 |
| US20230090742A1 (en) * | 2020-01-30 | 2023-03-23 | Sumitomo Pharma Oncology, Inc. | Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors |
| CN116528869A (zh) * | 2020-11-27 | 2023-08-01 | 安锐生物医药科技(广州)有限公司 | 氨基杂芳基激酶抑制剂 |
| CN114105887B (zh) * | 2021-09-16 | 2023-12-01 | 沈阳药科大学 | 一种氨基嘧啶衍生物及其制备方法和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0164204A1 (de) * | 1984-05-12 | 1985-12-11 | FISONS plc | Pharmazeutisch nützliche Pyrimidine |
| EP0162204A3 (de) * | 1984-05-22 | 1988-07-06 | Franz Grimme Landmaschinenfabrik GmbH & Co. KG. | Riemenschloss für Riemen von Siebkettenförderbändern |
| EP0233461B2 (de) * | 1986-01-13 | 2002-05-29 | American Cyanamid Company | 4,5,6-Substituierte 2-Pyrimidinamine |
| US4966622A (en) * | 1988-04-12 | 1990-10-30 | Ciba-Geigy Corporation | N-phenyl-N-pyrimidin-2-ylureas |
| GB9012592D0 (en) * | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
| US5516775A (en) * | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
| GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| NZ506679A (en) * | 1998-03-27 | 2002-11-26 | Janssen Pharmaceutica Nv | HIV inhibiting pyrimidine derivatives |
| CN1312807A (zh) * | 1998-06-19 | 2001-09-12 | 希龙公司 | 糖元合成酶激酶3的抑制剂 |
| GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| ATE430742T1 (de) * | 2000-12-21 | 2009-05-15 | Smithkline Beecham Corp | Pyrimidinamine als angiogenesemodulatoren |
| HUP0401711A3 (en) * | 2001-06-26 | 2009-07-28 | Bristol Myers Squibb Co | N-heterocyclic inhibitors of tnf-alpha and pharmaceutical compositions containing them |
| US6939874B2 (en) * | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
| EP1438053B1 (de) * | 2001-10-17 | 2008-09-10 | Boehringer Ingelheim Pharma GmbH & Co.KG | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
-
2002
- 2002-10-29 IL IL16166302A patent/IL161663A0/xx unknown
- 2002-10-29 EP EP02802307A patent/EP1442024B1/de not_active Expired - Lifetime
- 2002-10-29 CN CNB028219163A patent/CN100436427C/zh not_active Expired - Fee Related
- 2002-10-29 EA EA200400616A patent/EA007063B1/ru not_active IP Right Cessation
- 2002-10-29 AT AT02802307T patent/ATE389638T1/de active
- 2002-10-29 BR BR0213790-9A patent/BR0213790A/pt not_active IP Right Cessation
- 2002-10-29 HU HU0402245A patent/HUP0402245A3/hu unknown
- 2002-10-29 DK DK02802307T patent/DK1442024T3/da active
- 2002-10-29 NZ NZ531854A patent/NZ531854A/xx not_active IP Right Cessation
- 2002-10-29 MX MXPA04004176A patent/MXPA04004176A/es active IP Right Grant
- 2002-10-29 US US10/493,446 patent/US20060063789A1/en not_active Abandoned
- 2002-10-29 KR KR10-2004-7004829A patent/KR20040062557A/ko not_active Abandoned
- 2002-10-29 PT PT02802307T patent/PT1442024E/pt unknown
- 2002-10-29 JP JP2003540159A patent/JP2005507420A/ja active Pending
- 2002-10-29 DE DE60225709T patent/DE60225709T2/de not_active Expired - Lifetime
- 2002-10-29 WO PCT/EP2002/012079 patent/WO2003037877A1/en not_active Ceased
- 2002-10-29 AU AU2002363177A patent/AU2002363177B2/en not_active Ceased
- 2002-10-29 ES ES02802307T patent/ES2303565T3/es not_active Expired - Lifetime
- 2002-10-29 PL PL02368920A patent/PL368920A1/xx not_active Application Discontinuation
- 2002-10-29 CA CA002463823A patent/CA2463823A1/en not_active Abandoned
-
2004
- 2004-06-01 NO NO20042253A patent/NO326889B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ531854A (en) | 2006-03-31 |
| WO2003037877A1 (en) | 2003-05-08 |
| PL368920A1 (en) | 2005-04-04 |
| EA200400616A1 (ru) | 2004-08-26 |
| ES2303565T3 (es) | 2008-08-16 |
| HUP0402245A3 (en) | 2010-03-29 |
| AU2002363177B2 (en) | 2008-09-18 |
| EP1442024A1 (de) | 2004-08-04 |
| JP2005507420A (ja) | 2005-03-17 |
| KR20040062557A (ko) | 2004-07-07 |
| IL161663A0 (en) | 2004-09-27 |
| MXPA04004176A (es) | 2004-09-06 |
| CN100436427C (zh) | 2008-11-26 |
| DE60225709T2 (de) | 2009-05-07 |
| DE60225709D1 (de) | 2008-04-30 |
| CN1703405A (zh) | 2005-11-30 |
| CA2463823A1 (en) | 2003-05-08 |
| NO20042253L (no) | 2004-06-01 |
| PT1442024E (pt) | 2008-06-12 |
| US20060063789A1 (en) | 2006-03-23 |
| EP1442024B1 (de) | 2008-03-19 |
| HUP0402245A2 (hu) | 2005-02-28 |
| DK1442024T3 (da) | 2008-06-30 |
| NO326889B1 (no) | 2009-03-16 |
| EA007063B1 (ru) | 2006-06-30 |
| BR0213790A (pt) | 2004-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE389638T1 (de) | Aminobenzamidderivate als inhibitoren der glycogensynthasekinase-3- | |
| CY1106132T1 (el) | Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου | |
| ATE491703T1 (de) | Phthalazinonderivate | |
| DE60309848D1 (de) | Purinderivate als kinaseinhibitoren | |
| TR200201506T2 (tr) | Terapötik maddeler olarak kinaz inhibitörleri | |
| CY1114829T1 (el) | Συνεργιστικοι συνδυασμοι που περιλαμβανουν αναστολεα ρενινης για καρδιαγγειακες παθησεις | |
| SE0000540D0 (sv) | New compounds | |
| TW200503724A (en) | Novel pharmaceuticals | |
| DE60321808D1 (de) | Flavon derivate als inhibitoren von cyclin-abhängigen kinasen | |
| GB0100889D0 (en) | Compounds | |
| ATE449099T1 (de) | Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren | |
| NO20042080L (no) | Inhibitorer for post-prolin spaltningsproteaser | |
| DK1761520T3 (da) | Kinaseinhibitorer | |
| TW200602322A (en) | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | |
| IL163777A0 (en) | Kinase inhibitors | |
| TNSN07348A1 (en) | Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor | |
| ATE409189T1 (de) | Farnesyl transferase-hemmende 6- heterocyclylmethyl-chinolin und chinazol-derivate | |
| CY1109234T1 (el) | Αναστολεις κινασης | |
| BR0313969A (pt) | Inibidores de oxitocina | |
| DE60229420D1 (de) | Neue metallproteinaseinhibitoren | |
| ITMI20021391A1 (it) | Nitroderivati di inibitori della cicloossigenasi-2 | |
| EA200600607A1 (ru) | Производные имидазопиридина в качестве ингибиторов индуцируемой no-синтазы | |
| CY1111081T1 (el) | Νεα μεθοδος συνθεσης του (7-μεθοξυ-1-ναφθυλ) ακετονιτριλιου και εφαρμογη στη συνθεση της αγκομελατινης | |
| EA200801145A1 (ru) | Спироциклические производные хиназолина в качестве ингибиторов pde7 | |
| NO20050871L (no) | 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1442024 Country of ref document: EP |